Diabetic Nephropathy-Pipeline Review, H2 2016

Diabetic Nephropathy-Pipeline Review, H2 2016


  • Products Id :- GMDHC8347IDB
  • |
  • Pages: 220
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Diabetic Nephropathy-Pipeline Review, H2 2016

Summary

Global Markets Direct's, Diabetic Nephropathy-Pipeline Review, H2 2016', provides an overview of the Diabetic Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy

The report reviews pipeline therapeutics for Diabetic Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Diabetic Nephropathy therapeutics and enlists all their major and minor projects

The report assesses Diabetic Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Diabetic Nephropathy

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Diabetic Nephropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diabetic Nephropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Diabetic Nephropathy Overview 9

Therapeutics Development 10

Pipeline Products for Diabetic Nephropathy-Overview 10

Pipeline Products for Diabetic Nephropathy-Comparative Analysis 11

Diabetic Nephropathy-Therapeutics under Development by Companies 12

Diabetic Nephropathy-Therapeutics under Investigation by Universities/Institutes 15

Diabetic Nephropathy-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Diabetic Nephropathy-Products under Development by Companies 20

Diabetic Nephropathy-Products under Investigation by Universities/Institutes 23

Diabetic Nephropathy-Companies Involved in Therapeutics Development 24

AbbVie Inc 24

Ampio Pharmaceuticals, Inc. 25

Antisense Therapeutics Limited 26

Araim Pharmaceuticals, Inc. 27

Arena Pharmaceuticals, Inc. 28

Astellas Pharma Inc. 29

AstraZeneca Plc 30

Bayer AG 31

BiOrion Technologies B.V. 32

Boehringer Ingelheim GmbH 33

Cellmid Limited 34

ChemoCentryx, Inc. 35

CSL Limited 36

Daiichi Sankyo Company, Limited 37

Dimerix Bioscience Pty Ltd 38

Dong Wha Pharma Co., Ltd. 39

Dynamis Therapeutics, Inc. 40

Eli Lilly and Company 41

Galectin Therapeutics, Inc. 42

GenKyoTex S.A. 43

Gilead Sciences, Inc. 44

GlaxoSmithKline Plc 45

Glucox Biotech AB 46

GNI Group Ltd. 47

Islet Sciences, Inc. 48

Jenrin Discovery, Inc. 49

Johnson & Johnson 50

Mallinckrodt Plc 51

Mesoblast Limited 52

Mitsubishi Tanabe Pharma Corporation 53

MorphoSys AG 54

Noxxon Pharma AG 55

Omeros Corporation 56

Otsuka Holdings Co., Ltd. 57

PhytoHealth Corporation 58

ProMetic Life Sciences Inc. 59

Serodus ASA 60

Takeda Pharmaceutical Company Limited 61

Theravance Biopharma, Inc. 62

Tobira Therapeutics, Inc. 63

Vascular Pharmaceuticals, Inc. 64

Vicore Pharma AB 65

Diabetic Nephropathy-Therapeutics Assessment 66

Assessment by Monotherapy Products 66

Assessment by Target 67

Assessment by Mechanism of Action 70

Assessment by Route of Administration 74

Assessment by Molecule Type 76

Drug Profiles 78

11-RVIVIT-Drug Profile 78

A-717-Drug Profile 79

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology-Drug Profile 80

APD-371-Drug Profile 81

APX-115-Drug Profile 82

ASP-8232-Drug Profile 83

ATL-1103-Drug Profile 84

atrasentan hydrochloride-Drug Profile 91

baricitinib-Drug Profile 93

BI-703704-Drug Profile 100

BOT-191-Drug Profile 101

C-21-Drug Profile 102

canagliflozin-Drug Profile 104

CCX-140-Drug Profile 111

cenicriviroc mesylate-Drug Profile 115

cibinetide-Drug Profile 122

corticotropin-Drug Profile 125

CS-3150-Drug Profile 127

CSL-346-Drug Profile 129

Cyndacel-M-Drug Profile 130

danazol-Drug Profile 131

DMX-250-Drug Profile 135

DT-23552-Drug Profile 136

DW-1029M-Drug Profile 137

DYN-12-Drug Profile 138

emapticap pegol-Drug Profile 140

finerenone-Drug Profile 142

GKT-136901-Drug Profile 144

GKT-831-Drug Profile 145

GRMD-02-Drug Profile 148

GW-610742-Drug Profile 158

IP-9-Drug Profile 159

JD-5037-Drug Profile 160

JNJ-39933673-Drug Profile 161

MG-132-Drug Profile 162

Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications-Drug Profile 163

MOR-107-Drug Profile 165

MPC-300IV-Drug Profile 166

MT-3995-Drug Profile 170

Nephrilin-Drug Profile 171

Orbcel-M-Drug Profile 172

oxypurinol-Drug Profile 173

PBI-4050-Drug Profile 174

PBI-4547-Drug Profile 179

PHN-033-Drug Profile 180

pirfenidone-Drug Profile 181

probucol-Drug Profile 182

selonsertib-Drug Profile 183

SER-150-Drug Profile 184

Small Molecule to Inhibit NOX-4 for Diabetic Nephropathy-Drug Profile 187

Small Molecules for Diabetic Nephropathy-Drug Profile 188

Small Molecules to Inhibit Heparanase for Metastatic Cancer and Diabetic Nephropathy-Drug Profile 189

Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders-Drug Profile 190

SP-20202-Drug Profile 192

TAK-272-Drug Profile 193

TBE-31-Drug Profile 194

TD-0714-Drug Profile 195

VPI-2690B-Drug Profile 197

VS-105-Drug Profile 198

XRX-108-Drug Profile 199

XRX-221-Drug Profile 200

Diabetic Nephropathy-Dormant Projects 201

Diabetic Nephropathy-Discontinued Products 204

Diabetic Nephropathy-Product Development Milestones 205

Featured News & Press Releases 205

Appendix 215

Methodology 215

Coverage 215

Secondary Research 215

Primary Research 215

Expert Panel Validation 215

Contact Us 215

Disclaimer 216

List of Tables

Number of Products under Development for Diabetic Nephropathy, H2 2016 14

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Development by Companies, H2 2016 (Contd..1) 17

Number of Products under Development by Companies, H2 2016 (Contd..2) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Late Stage Development, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Comparative Analysis by Unknown Stage Development, H2 2016 23

Products under Development by Companies, H2 2016 24

Products under Development by Companies, H2 2016 (Contd..1) 25

Products under Development by Companies, H2 2016 (Contd..2) 26

Products under Investigation by Universities/Institutes, H2 2016 27

Diabetic Nephropathy-Pipeline by AbbVie Inc, H2 2016 28

Diabetic Nephropathy-Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 29

Diabetic Nephropathy-Pipeline by Antisense Therapeutics Limited, H2 2016 30

Diabetic Nephropathy-Pipeline by Araim Pharmaceuticals, Inc., H2 2016 31

Diabetic Nephropathy-Pipeline by Arena Pharmaceuticals, Inc., H2 2016 32

Diabetic Nephropathy-Pipeline by Astellas Pharma Inc., H2 2016 33

Diabetic Nephropathy-Pipeline by AstraZeneca Plc, H2 2016 34

Diabetic Nephropathy-Pipeline by Bayer AG, H2 2016 35

Diabetic Nephropathy-Pipeline by BiOrion Technologies B.V., H2 2016 36

Diabetic Nephropathy-Pipeline by Boehringer Ingelheim GmbH, H2 2016 37

Diabetic Nephropathy-Pipeline by Cellmid Limited, H2 2016 38

Diabetic Nephropathy-Pipeline by ChemoCentryx, Inc., H2 2016 39

Diabetic Nephropathy-Pipeline by CSL Limited, H2 2016 40

Diabetic Nephropathy-Pipeline by Daiichi Sankyo Company, Limited, H2 2016 41

Diabetic Nephropathy-Pipeline by Dimerix Bioscience Pty Ltd, H2 2016 42

Diabetic Nephropathy-Pipeline by Dong Wha Pharma Co., Ltd., H2 2016 43

Diabetic Nephropathy-Pipeline by Dynamis Therapeutics, Inc., H2 2016 44

Diabetic Nephropathy-Pipeline by Eli Lilly and Company, H2 2016 45

Diabetic Nephropathy-Pipeline by Galectin Therapeutics, Inc., H2 2016 46

Diabetic Nephropathy-Pipeline by GenKyoTex S.A., H2 2016 47

Diabetic Nephropathy-Pipeline by Gilead Sciences, Inc., H2 2016 48

Diabetic Nephropathy-Pipeline by GlaxoSmithKline Plc, H2 2016 49

Diabetic Nephropathy-Pipeline by Glucox Biotech AB, H2 2016 50

Diabetic Nephropathy-Pipeline by GNI Group Ltd., H2 2016 51

Diabetic Nephropathy-Pipeline by Islet Sciences, Inc., H2 2016 52

Diabetic Nephropathy-Pipeline by Jenrin Discovery, Inc., H2 2016 53

Diabetic Nephropathy-Pipeline by Johnson & Johnson, H2 2016 54

Diabetic Nephropathy-Pipeline by Mallinckrodt Plc, H2 2016 55

Diabetic Nephropathy-Pipeline by Mesoblast Limited, H2 2016 56

Diabetic Nephropathy-Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 57

Diabetic Nephropathy-Pipeline by MorphoSys AG, H2 2016 58

Diabetic Nephropathy-Pipeline by Noxxon Pharma AG, H2 2016 59

Diabetic Nephropathy-Pipeline by Omeros Corporation, H2 2016 60

Diabetic Nephropathy-Pipeline by Otsuka Holdings Co., Ltd., H2 2016 61

Diabetic Nephropathy-Pipeline by PhytoHealth Corporation, H2 2016 62

Diabetic Nephropathy-Pipeline by ProMetic Life Sciences Inc., H2 2016 63

Diabetic Nephropathy-Pipeline by Serodus ASA, H2 2016 64

Diabetic Nephropathy-Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 65

Diabetic Nephropathy-Pipeline by Theravance Biopharma, Inc., H2 2016 66

Diabetic Nephropathy-Pipeline by Tobira Therapeutics, Inc., H2 2016 67

Diabetic Nephropathy-Pipeline by Vascular Pharmaceuticals, Inc., H2 2016 68

Diabetic Nephropathy-Pipeline by Vicore Pharma AB, H2 2016 69

Assessment by Monotherapy Products, H2 2016 70

Number of Products by Stage and Target, H2 2016 72

Number of Products by Stage and Mechanism of Action, H2 2016 75

Number of Products by Stage and Route of Administration, H2 2016 79

Number of Products by Stage and Molecule Type, H2 2016 81

Diabetic Nephropathy-Dormant Projects, H2 2016 205

Diabetic Nephropathy-Dormant Projects (Contd..1), H2 2016 206

Diabetic Nephropathy-Dormant Projects (Contd..2), H2 2016 207

Diabetic Nephropathy-Discontinued Products, H2 2016 208

List of Figures

Number of Products under Development for Diabetic Nephropathy, H2 2016 14

Number of Products under Development for Diabetic Nephropathy-Comparative Analysis, H2 2016 15

Number of Products under Development by Companies, H2 2016 16

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 70

Number of Products by Top 10 Targets, H2 2016 71

Number of Products by Stage and Top 10 Targets, H2 2016 71

Number of Products by Top 10 Mechanism of Actions, H2 2016 74

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 74

Number of Products by Routes of Administration, H2 2016 78

Number of Products by Stage and Routes of Administration, H2 2016 78

Number of Products by Top 10 Molecule Types, H2 2016 80

Number of Products by Stage and Top 10 Molecule Types, H2 2016 80

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

AbbVie Inc

Ampio Pharmaceuticals, Inc.

Antisense Therapeutics Limited

Araim Pharmaceuticals, Inc.

Arena Pharmaceuticals, Inc.

Astellas Pharma Inc.

AstraZeneca Plc

Bayer AG

BiOrion Technologies B.V.

Boehringer Ingelheim GmbH

Cellmid Limited

ChemoCentryx, Inc.

CSL Limited

Daiichi Sankyo Company, Limited

Dimerix Bioscience Pty Ltd

Dong Wha Pharma Co., Ltd.

Dynamis Therapeutics, Inc.

Eli Lilly and Company

Galectin Therapeutics, Inc.

GenKyoTex S.A.

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Glucox Biotech AB

GNI Group Ltd.

Islet Sciences, Inc.

Jenrin Discovery, Inc.

Johnson & Johnson

Mallinckrodt Plc

Mesoblast Limited

Mitsubishi Tanabe Pharma Corporation

MorphoSys AG

Noxxon Pharma AG

Omeros Corporation

Otsuka Holdings Co., Ltd.

PhytoHealth Corporation

ProMetic Life Sciences Inc.

Serodus ASA

Takeda Pharmaceutical Company Limited

Theravance Biopharma, Inc.

Tobira Therapeutics, Inc.

Vascular Pharmaceuticals, Inc.

Vicore Pharma AB

Diabetic Nephropathy Therapeutic Products under Development, Key Players in Diabetic Nephropathy Therapeutics, Diabetic Nephropathy Pipeline Overview, Diabetic Nephropathy Pipeline, Diabetic Nephropathy Pipeline Assessment

select a license
Single User License
USD 2000 INR 143120
Site License
USD 4000 INR 286240
Corporate User License
USD 6000 INR 429360

NEWSLETTER BY CATEGORY




Testimonials

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com